Metabolic and quality of life effects of growth hormone replacement in patients with TBI and AGHD: A pilot study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

Who Took Part

By PubMed's age tags, the people studied were adults.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

Secondary outcomes included body composition, physical and cognitive function, psychological and somatic symptoms, physical activity, IGF-1 levels and safety parameters.

What Was Measured

The subject headings attached to it are Growth Hormone, Quality of Life, Pilot Projects, Human Growth Hormone, Dwarfism, Pituitary, Brain Injuries, Traumatic and Hormone Replacement Therapy.

The authors tagged it with the keywords Adult growth hormone deficiency, Combat veterans, Growth hormone replacement therapy, OEF/OIF/OND, Post-traumatic hypopituitarism and Traumatic brain injury.

What This Means in Plain Language

The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.